Seroprevalence of SARS-CoV-2 antibodies among children and adolescents recruited in a malariometric survey in north-eastern Tanzania July 2021

Eric Lyimo1,2*, Cyrielle Fougeroux3, Anangisye Malabeja1, Joyce Mbwana1, Paul M. Hayuma1, Edwin Liheluka1, Louise Turner2,4, Samwel Gesase1, Thomas Lavstsen2,4, John P. A. Lusingu1,2, Daniel T. R. Minja1 and Christian W. Wang2,4

Abstract

Background: African countries stand out globally as the region seemingly least affected by the COVID-19 pandemic, caused by the virus SARS-CoV-2. Besides a younger population and potential pre-existing immunity to a SARS-CoV-2-like virus, it has been hypothesized that co-infection or recent history of Plasmodium falciparum malaria may be protective of COVID-19 severity and mortality. The number of COVID-19 cases and deaths, however, may be vastly undercounted. Very little is known about the extent to which the Tanzanian population has been exposed to SARS-CoV-2. Here, we investigated the seroprevalence of IgG to SARS-CoV-2 spike protein in two Tanzanian rural communities 1½ years into the pandemic and the association of coinciding malaria infection and exposure.

Methods: During a malariometric survey in July 2021 in two villages in north-eastern Tanzania, blood samples were taken from 501 participants (0–19 years old). Malaria was detected by mRDT and microscopy. Levels of IgG against the spike protein of SARS-CoV-2 were measured by ELISA as well as IgG against five different antigens of P. falciparum; CIDRa1.1, CIDRa1.4 and CIDRa1.5 of PfEMP1 and GLURP and MSP3.

Results: The seroprevalence of SARS-CoV-2 IgG was 39.7% (106/267) in Kwamasimba and 32.5% (76/234) in Mkokola. In both villages the odds of being seropositive increased significantly with age (AOR = 1.12, 95% CI 1.07–1.17, \( p < 0.001 \)). P. falciparum malaria prevalence by blood smear microscopy was 7.9% in Kwamasimba and 2.1% in Mkokola. 81.3% and 70.5% in Kwamasimba and Mkokola, respectively, showed recognition of minimum one malaria antigen. Residing in Kwamasimba was associated with a broader recognition (AOR = 1.91, 95% CI 1.34–2.71, \( p < 0.001 \)). The recognition of malaria antigens increased significantly with age in both villages (AOR = 1.12; 95% CI 1.08–1.16, \( p < 0.001 \)). Being SARS-CoV-2 seropositive did not associate with the breadth of malaria antigen recognition when adjusting for age (AOR = 0.99; 95% CI 0.83–1.18; \( p = 0.91 \)).

Conclusion: More than a third of the children and adolescents in two rural communities in Tanzania had antibodies to SARS-CoV-2. In particular, the adolescents were seropositive but being seropositive did not associate with the...
Introduction

The coronavirus, severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) causing COVID-19, was first reported in Wuhan, China in December 2019 [1, 2]. SARS-CoV-2 belongs to the subfamily of Coronavirinae and genome analyses showed a close relationship with the highly pathogenic strain, SARS-CoV [3, 4]. The positive-sense single-stranded RNA virus is easily transmitted from human to human [4] and has since its discovery spread to all continents leading to the COVID-19 pandemic. The symptoms of the disease range from mild flu-like, including cough and fever, to life-threatening complications. However, even people without symptoms or with a mild course of the disease can transmit the virus [5, 6].

In Africa, when the pandemic occurred, there were major public health concerns due to the existing high prevalence rates for both infectious and non-infectious diseases and the putative adverse consequences of COVID-19 preventive lockdown measures on the prevention and management of other infectious diseases such as malaria [7].

The latest WHO world malaria report revealed an estimated 241 million malaria cases worldwide in 2020 [8]; an increase of 14 million from the previous year [9] resulting in an increase of 12% in malaria deaths to an estimated 627,000. The African region accounted for 96% of all malaria related deaths. Sixty-eight percent (i.e. 47,000) of the estimated additional deaths are believed to be due to service disruptions in the provision of malaria prevention campaigns [8, 10]. Tanzania accounted for 4.1% of all malaria related deaths globally in 2020 [8]. The government of Tanzania decided not to implement a lockdown that would otherwise restrict public access to health services and prevent citizens from working and thereby affecting the ability to afford food and health care, fostering the negative impact of the pandemic [11]. In February 2021, however, the government re-issued guidelines insisting on WHO-recommended measures in the fight against the spread of SARS-CoV2, built local capacity to produce personal protective equipment and on July 24, 2021, the first shipment of COVID-19 vaccines through COVAX was received.

Intriguingly, African countries including Tanzania, stand out globally as the region seemingly least affected by the COVID-19 pandemic as compared to North America and Europe. Besides a younger population and potential pre-existing immunity to a SARS-CoV-2-like virus [12, 13], it has been hypothesized that co-infections or a recent history of Plasmodium falciparum malaria infection may be protective of COVID-19 severity and mortality [14, 15]. The number of COVID-19 cases and deaths, however, may be vastly undercounted [16], and a new study reports high seroprevalence across several African countries suggesting higher exposure to SARS-CoV-2 and protection against COVID-19 disease than indicated by surveillance data [17].

Little is known as to what extent the Tanzanian population has been exposed to SARS-CoV-2. So far around 39,000 confirmed cases and 845 deaths due to COVID-19 have been reported to the WHO since the 3rd of January 2020 with the majority (20,607 cases and 553 deaths) reported on the 2nd of August 2021 [18]. Here, as the first to our knowledge, we investigated the seroprevalence of immunoglobulin G (IgG) to SARS-CoV-2 spike protein in a Tanzanian population. The spike protein of the virus binds to host cell surface angiotensin-converting enzyme 2 (ACE2) to initiate entry and cause infection [19] and is the known target of protective immunity [20–22]. IgG targeting SARS-CoV-2 spike protein was measured in plasma from children and adolescents in two rural communities of Kwamasimba (highland village) and Mkokola (lowland village,) in Korogwe District in north-eastern Tanzania. This was done during a malariometric survey in July 2021, just days before the highest recorded number of cases in Tanzania [18].

We further investigated the seroprevalence of spike protein-specific IgG in relation to the prevalence of malaria and the breadth of IgG reactivity to five different antigens of P. falciparum. These antigens were three cysteine-rich interdomain region (CIDR) domains (CIDRα1.1, CIDRα1.4 and CIDRα1.5) of P. falciparum erythrocyte membrane protein 1 (PfEMP1) associated with the sequestration of infected erythrocytes and severe malaria [23, 24], and two proteins associated with the parasite’s merozoite stage: glutamate-rich protein (GLURP) and merozoite surface protein 3 (MSP3) [25]. Lastly, we investigated if any clinical and demographic data were associated with that of being SARS-CoV-2 seropositive.

Keywords: COVID-19, Seroprevalence, Spike-protein, Malaria
Methods

Study site and population
A cross-sectional survey was conducted in two rural villages, highland Kwamasimba (KWA) (700 m above sea level) and lowland Mkokola (MKL) (300 m above sea level). The villages are located in Korogwe District, about 100 km from the Indian Ocean coastline and Tanga City in north-eastern Tanzania. According to an updated census survey the population sizes of Kwamasimba and Mkokola were around 2000 each (Malaria Research and Capacity building for field trials in Tanzania (MaReCa) Census survey 2018) during the cross-sectional survey. The economic activities are mainly subsistence farming and petty trading. The study communities have been participating in annual surveys since 2003 when the prevalence of P. falciparum malaria was higher in Mkokola (78%) than in Kwamasimba (25%) [26] whereas in 2018 the overall point prevalence was 14.3% [27]. The overall malaria prevalence from 2009 to 2021 shows contrasting trends for the two villages (manuscript in preparation). The study population included individuals aged between 0 and 19 years old. Malaria rapid diagnostic test (mRDT) results and haemoglobin levels using HemoCue® (Ångelholm, Sweden) were obtained on site and blood smears for microscopy were prepared at the National Institute for Medical Research, Korogwe Research Laboratory. Study participants who were diagnosed with malaria (mRDT) and with or without anaemia were given appropriate drugs administered as per existing treatment guidelines. Additionally, other diseases such as diarrhoea and skin fungal infections were managed as per the clinician’s discretion.

Malarialometric survey
The cross-sectional survey was conducted from the 19th to the 30th of July 2021 to determine the malaria point prevalence in children and adolescents aged between 0 and 19 years old as previously done [27]. During the survey, participants were asked to provide venous blood samples, which were collected in ethylenediaminetetraacetic acid (EDTA) vacutainers. Participants were randomly selected in stratified age groups (0 to 19) and 529 participants were eligible for enrolment of which 501 provided whole blood enough for further analyses. During the survey, a paper-based questionnaire administered by trained clinicians was used to record demographic and clinical data. Clinical symptoms related to malaria in the previous 2 days prior to the survey were recorded and included fever, headache, loss of appetite, vomiting, coughing, and body weakness. Flu was recorded as well to determine whether the symptoms could be ascribed to other causes of febrile illnesses other than malaria. Also, the study participants were asked if they had taken any anti-malaria medication within 14 days prior to the survey date. Throughout the survey, malaria cases were treated per national guidelines based on mRDT results (CareStart™ Malaria Pf/Pv (HRP2/pLDH) Ag Combo RDT (AccessBio, US)). Thick and thin film blood smears were analysed for the presence of Plasmodium and for species determination, respectively. The blood slides were prepared using a premade template for quantification of parasite densities and determination of Plasmodium species, respectively. The blood slides were fixed with methanol and stained with 5% Giemsa for 20 min and depending on parasite density, parasite count was reported against 200 or 500 white blood cells. Two independent microscopists blinded of the mRDT results, who participate in malaria microscopy proficiency testing, read the blood smears. Plasma samples were obtained by centrifugation of the venous blood and stored at −80 °C until further testing. During the survey, all national guidelines for the prevention of COVID-19 were followed, including wearing face masks, handwashing, use of hand sanitizers, and distancing whenever possible.

SARS-CoV-2 spike IgG ELISA
Plasma samples were analysed for SARS-CoV-2 spike IgG titres as described elsewhere [28] with slight modification. Briefly, the 96-well microtiter plates (Nunc MaxiSorp) were coated overnight at 4 °C with 2 µg/mL of recombinant ExpreS2 produced SARS-CoV-2 spike protein in kind contribution from Expres2ion Biotechnologies (amino acid 16-1208, from ABNCoV2 phase I/II study, manuscript in prep.) diluted in PBS. Plates were blocked with 3% skimmed milk in PBST (PBS and 0.1% Tween 20) for 1 h at room temperature. Plasma samples were diluted 1:200 with 1% skimmed milk in PBST and 50 µL was added into each well followed by 2 h incubation at room temperature. Microtiterplates were washed three times with PBST, and to detect bound human IgG, rabbit anti-human IgG horseradish peroxidase (HRP) conjugated antibody (Dako, P0214) was then added (1:4000) and incubated at room temperature for 1 h. TMB was added following manufacturer’s instruction and optical densities (ODs) were read at 450 nm. One hundred samples collected from the same two villages in the years 2015 to 2019 were randomly selected and used as negative control and seropositivity was determined as values above three standard deviations of the mean of the 2015 and 2019 samples [29]. To validate the procedure a positive control from WHO (pooled plasma obtained from 11 individuals recovered from SARS-CoV-2 infection) [30], a positive control from a Danish convalescent patient (unknown time of disease) and seven negative pre-COVID-19 Danish donor plasma samples were used in the ELISAs.
PFEMP1, GLURPR2 and MSP3 IgG ELISA
IgG levels against recombinant domains of three different PFEMP1s (CIDRα1.1, CIDRα1.4 and CIDRα1.5), GLURPR2 and MSP3 [31, 32] were determined in plasma samples as previously described [33]. Sandwich enzyme-linked immunosorbent assay (ELISA) was performed, in brief, for each antigen 5 µg/mL was coated in 96-well microtiterplates (Nunc MaxiSorp) over night at 4 °C. The microplates were blocked with 3% skimmed milk in PBS for 1 h at room temperature. Plasma samples at 1:40 dilution were incubated for 1 h at room temperature and washed three times. To detect bound human IgG, rabbit anti-human IgGHRP conjugated antibody (Dako, P0214) was added (1:3000) and then incubated for 1 h at room temperature followed by three times wash. To detect bound human IgG, TMB (T5525, Sigma-Aldrich) was added following manufacturer’s instruction. Optical densities (ODs) were read at 450 nm on a microtiterplate reader (Multiskan FC, Thermo Scientific). To determine seropositivity the analysis included seven plasma samples from naïve Danish donors as negative controls and the cut-off was set as values above three standard deviations of the mean of the naïve samples. The IgG reactivity to the five antigens was used to generate a score of breadth of malaria antigen recognition of each participant from 0 to 5.

Data management and analysis
The demographic and clinical data were collected on a paper-based questionnaire and then double-entered into a Microsoft Access database, validated and transferred into Stata v13.0 (Stata Corporation, Texas, USA) for cleaning and merging with ELISA OD values. Statistical analyses were done in STATA and GraphPad Prism v8.4.2 (San Diego, California, USA). In proportional tests, data are presented as percentages, medians, and Chi-square. The Wilcoxon rank-sum (Mann–Whitney) was used to assess the relationship between SARS-CoV-2 spike IgG OD values and malaria prevalence. The correlation between ordered age groups and seropositivity of COVID-19 and malaria was assessed using the Trend test across ordered groups. Multivariate logistic regressions were performed to assess the relationship between SARS-CoV-2 spike seropositivity with malaria prevalence, breadth of malaria antigen recognition, demographic, and clinical data. In the multivariate analysis, a forward selection was done for variables with \( p < 0.2 \) in the univariate analysis. A \( p \)-value of \( < 0.05 \) was considered statistically significant.

Results
Baseline characteristics of the study population by village of residence
In total, 501 study participants were enrolled during the July 2021 cross-sectional malariometric survey; 267 (53.3%) were from the highland village, Kwamasimba and 234 (46.7%) were from the lowland village, Mkokola (Table 1). The survey had a balancing proportion of both sexes (Table 1). The pre-COVID-19 analysis included 100 participants, 46 (46%) from Kwamasimba and 54 (54%) from Mkokola with a similar distribution of age and sex as in the 2021 survey (Additional file 1). In 2021, the \( P. falciparum \) malaria prevalence by mRDT was 15.4% in Kwamasimba and 6.4% in Mkokola, primarily among children above 5 years of age (Table 1). By blood smear microscopy, the prevalence was 7.9% in Kwamasimba with a median parasitaemia of 2123/µL and 2.1% in Mkokola with a median parasitaemia of 1080/µL. Bed net use was prominent in both villages (>93%). The study participants in Mkokola had more non-malarial fever (\( \chi^2 = 12.31, p < 0.001 \)) and diarrhoea (\( \chi^2 = 6.18, p < 0.013 \)) than in Kwamasimba, otherwise no marked differences in the clinical characteristics in the two villages was observed; such as haemoglobin levels, coughing, body weakness, headache, body or abdominal pain, loss of appetite, vomiting, and yellowness of eyes (Table 1).

Anti-SARS-CoV-2 seroprevalence
The IgG recognition of the SARS-CoV-2 spike protein of the 501 study participants and positive and negative controls are shown in Fig. 1. The difference in seroprevalence between the villages, 39.7% in Kwamasimba and 32.5% in Mkokola, was not statistically significant (\( \chi^2 = 2.8, p = 0.094 \)), however, the seropositivity increased with age in both villages from around 20% in the 1–4-year-olds (17.1% and 22.0% in Kwamasimba and Mkokola, respectively) to at least 50% in the older age group of 15–19 years; 68.6% and 50% in Kwamasimba and Mkokola, respectively) to at least 50% in the older age group of 15–19 years; 68.6% and 50% in Kwamasimba and Mkokola, respectively (Table 2). Among the <1-year olds the seroprevalence was 38.5% and 33.3% in Kwamasimba and Mkokola, respectively (Table 2). When combining the two villages, among the 0–5 months old: 55.6% (5/9) were seropositive and among the 6–11 months old: 26.3% (5/19) were seropositive but the difference was not statistically significant (Additional file 2).

Serorecognition of Plasmodium falciparum malaria antigens
The IgG reactivity in the 501 plasma samples to five \( P. falciparum \) derived antigens were evaluated by ELISA.
Table 1  Baseline characteristics of the study populations July 2021

|                      | VILLAGE                  | p-value |
|----------------------|--------------------------|---------|
|                      | Kwamasimba               | Mkokola |
| Age, N = 501, % (n)  |                          |         |
| < 1, % (n)           | 4.9 (13)                 | 6.4 (15) |
| 1–4, % (n)           | 15.4 (41)                | 21.4 (50) |
| 5–9, % (n)           | 28.1 (75)                | 32.5 (76) |
| 10–14, % (n)         | 38.6 (103)               | 26.0 (61) |
| 15–19, % (n)         | 13.0 (35)                | 13.7 (32) |
|                      |                          | 0.044   |
| Sex N = 501          |                          |         |
| Male, % (n)          | 52.1 (139)               | 46.1 (108) |
| Female, % (n)        | 47.9 (128)               | 53.8 (126) |
|                      |                          | 0.187   |
| Malaria prevalence by mRDT, N = 501 |            |         |
| Positive, % (n)      | 15.4 (41)                | 6.4 (15) |
| Negative, % (n)      | 84.6 (226)               | 93.6 (219) |
|                      |                          | 0.002   |
| Malaria prevalence by blood smear, N = 501 |            |         |
| Positive, % (n)      | 7.9 (21)                 | 2.1 (5) |
| Negative, % (n)      | 92.1 (246)               | 97.9 (229) |
|                      |                          | 0.004   |
| Parasites/µL blood, median, (IQR) | 2123 (995–7124)          | 1080 (985–1320) |
| Bed net use, N = 499 |                          |         |
| Yes, % (n)           | 93.3 (249)               | 99.6 (231) |
| No, % (n)            | 6.7 (18)                 | 0.4 (1) |
|                      |                          | 0.001   |
| Hb, mean (CI 95%)    | 11.9 (11.7–12.0)         | 12.4 (12.3–12.7) |
|                      | Kwamasimba n = 245       | Mkokola n = 229 |
| Fever (%) and malaria negative by blood smear | 13.1 (32) | 25.8 (59) | 0.001 |
|                      | Coughing, N = 500        |         |
| Yes, % (n)           | 28.2 (75)                | 40.6 (95) |
| No, % (n)            | 71.8 (191)               | 59.4 (139) |
|                      |                          | 0.003   |
| Body weakness, N = 500 |                      |         |
| Yes, % (n)           | 2.6 (7)                  | 5.1 (12) |
| No, % (n)            | 93.6 (249)               | 86.8 (203) |
| NA, % (n)            | 3.8 (10)                 | 8.1 (19) |
|                      |                          | 0.034   |
| Headache, N = 500    |                          |         |
| Yes, % (n)           | 18.8 (50)                | 25.6 (60) |
| No, % (n)            | 76.7 (204)               | 66.7 (156) |
| NA, % (n)            | 4.5 (12)                 | 7.7 (18) |
|                      |                          | 0.039   |
| Body pain, N = 498   |                          |         |
| Yes, % (n)           | 3.7 (10)                 | 4.3 (10) |
| No, % (n)            | 91.7 (243)               | 86.3 (201) |
| NA, % (n)            | 4.4 (12)                 | 9.4 (22) |
|                      |                          | 0.087   |
| Abdominal pain, N = 499 |                      |         |
| Yes, % (n)           | 16.6 (44)                | 23.5 (55) |
| No, % (n)            | 78.9 (206)               | 67.9 (159) |
| NA, % (n)            | 4.5 (12)                 | 8.6 (20) |
|                      |                          | 0.017   |
| Diarrhoea, N = 500   |                          |         |
| Yes, % (n)           | 6.0 (16)                 | 12.4 (29) |
| No, % (n)            | 94.0 (250)               | 87.6 (205) |
|                      |                          | 0.013   |
| Loss of appetite, N = 500 |                      |         |
| Yes, % (n)           | 3.4 (9)                  | 6.0 (14) |
| No, % (n)            | 93.2 (248)               | 87.2 (204) |
Most study participants, 81.3% and 70.5% (χ² = 7.973, p = 0.005) in Kwamasimba and Mkokola, respectively, showed recognition of minimum one antigen (Fig. 2 and Table 2). The serorecognition of GLURP R2 (74.9% and 67.9% in Kwamasimba and Mkokola, respectively; χ² = 2.972, p = 0.09) and MSP3 (14.2% and 9.0% in Kwamasimba and Mkokola, respectively; χ² = 3.318, p = 0.07) was similar between the two villages. On the contrary, the serorecognition of the three PfEMP1 domains was significantly higher in Kwamasimba than in Mkokola: CIDRα1.1: 24.7% and 15.8% (χ² = 6.058, p = 0.01); CIDRα1.4: 38.6% and 24.4% (χ² = 11.597, p = 0.001); CIDRα1.5: 3.8% and 0.8% (χ² = 4.457, p = 0.04), respectively. The number of malaria antigens recognized was significantly increased with age in both villages (Trend test across ordered groups, Kwamasimba, z-score = 4.90, p < 0.001, and Mkokola, z-score = 6.07, p < 0.001) (Table 2).

Association of SARS-CoV-2 seroprevalence and malaria

The association of SARS-CoV-2 seropositivity, malaria prevalence and breadth of malaria antigen recognition was explored by logistic regression (Table 3). There was no association between SARS-CoV-2 seropositivity and malaria prevalence, neither by mRDT nor blood smear microscopy (Table 3). Being SARS-CoV-2 seropositive was, however, associated with the breadth of malaria antigen recognition in the univariate regression analysis (OR = 1.17; 95% CI 1.01–1.36; p = 0.04) but in the multivariate regression analysis the association disappeared (AOR = 0.99; 95% CI 0.83–1.18; p = 0.91) (Table 3).

Association of SARS-CoV-2 seroprevalence and demographic and clinical data

The association of SARS-CoV-2 seropositivity and demographic and clinical characteristics was also explored by logistic regression (Table 4). The SARS-CoV-2 seropositivity did not associate with any of the investigated demographic and clinical data, with the exception of age where the risk of being seropositive increased significantly with age (AOR = 1.13, 95% CI 1.08–1.19, p < 0.001).

Association between breadth of malaria antigen recognition and demographic and clinical data

The association between the breadth of malaria antigen recognition and demographic and clinical data was explored by ordered logistic regression (Table 5). Residing in Kwamasimba was associated with a broader recognition of malaria antigens (AOR = 1.91 95% CI 1.34–2.71, p < 0.001) and the recognition increased significantly with age in both villages AOR = 1.12; 95% CI 1.08–1.16, p < 0.001). The breadth of malaria antigen recognition

Table 1 (continued)

|                           | Kwamasimba n = 245 | Mkokola n = 229 |
|---------------------------|--------------------|-----------------|
| NA, % (n)                 | 3.4 (9)            | 6.8 (16)        |
| Vomiting, N = 500         |                    |                 |
| Yes, % (n)                | 2.6 (7)            | 4.7 (11)        |
| No, % (n)                 | 97.4 (259)         | 95.3 (233)      |
| Yellowness of eyes, N = 499|                    |                 |
| Yes, % (n)                | 0.0 (0)            | 0.9 (2)         |
| No, % (n)                 | 100.0 (265)        | 99.1 (232)      |

Fig. 1  Anti-SARS-CoV-2 IgG levels measured in plasma from 501 individuals by ELISA during a cross-sectional survey in July 2021 in two rural villages Kwamasimba and Mkokola in north-eastern Tanzania, showing mean and standard deviation. The cut-off is represented by a dotted line. Plasma samples from before the COVID-19 pandemic were used as negative controls; a Danish convalescent sample and the WHO Standard [30] were used as positive control.
| Age groups | N | Kwamasimba | Malaria (BS) | Malaria (mRDT) | Malaria antigen recognition | SARS-CoV-2 seropositivity | Malaria (BS) | Malaria (mRDT) | Malaria antigen recognition | SARS-CoV-2 seropositivity |
|------------|---|------------|--------------|----------------|----------------------------|--------------------------|--------------|----------------|----------------------------|--------------------------|
| <1         | 28 | 13         | 38.5% (5)    | 0.0% (0)       | 46.2% (6)                  | 0.0% (0)                 | 15           | 33.3% (5)    | 40.0% (6)                  | 0.0% (0)                 |
| 1–4        | 91 | 41         | 17.1% (7)    | 0.0% (0)       | 65.9% (27)                 | 7.3% (3)                | 50           | 22.0% (11)   | 34.0% (17)                 | 4.0% (2)                 |
| 5–9        | 151| 75         | 25.3% (19)   | 6.7% (5)       | 78.7% (59)                 | 13.3% (10)              | 76           | 25.0% (19)   | 81.6% (62)                 | 1.3% (1)                 |
| 10–14      | 164| 103        | 49.5% (51)   | 10.7% (11)     | 89.3% (92)                 | 21.4% (22)              | 61           | 41.0% (25)   | 85.3% (52)                 | 1.6% (1)                 |
| 15–19      | 67 | 35         | 68.6% (24)   | 14.3% (5)      | 94.3% (33)                 | 17.1% (6)               | 32           | 50.0% (16)   | 87.5% (28)                 | 3.1% (1)                 |
| Total      | 501| 267        | 39.7% (106)  | 7.9% (21)      | 81.3% (217)                | 15.4% (41)              | 234          | 32.5% (76)   | 70.5% (165)                | 2.1% (5)                 |
| p-value    |    |            | 0.001        | 0.006          | 0.017                      |                          | 0.007        | 0.001         | 0.988                      | 0.221                    |
| z-score    |    |            | 4.75         | 2.74           | 2.38                       |                          | 2.67         | 6.07          | 0.02                       | 1.22                     |

Table 2: SARS-CoV-2 seropositivity, malaria prevalence and recognition of malaria antigens in Kwamasimba and Mkokola
was inversely associated with a previous 2-day clinical history of having fever (AOR = 0.41; 95% CI 0.25–0.67, \( p < 0.001 \)) and associated with not having body pain (AOR = 2.83; 95% CI 1.03–7.75, \( p < 0.04 \)).

**Discussion**

Serum antibody testing has the potential to detect previous COVID-19 infections. We therefore measured the seroprevalence of SARS-CoV-2 spike protein IgG in blood samples from two rural villages in Tanzania during the pandemic, July 2021. Around a third of the participants were positive for antibodies recognizing the spike protein and the seroprevalence increased with age, from ~20% in the 1–4-year-olds to ~60% in the 15–19-year-olds. Global seroprevalence has been estimated to be ~60% by September 2021 from either infection or vaccination, and children under 10 years and adults above 60 were less likely to be seropositive than 20–29-year-old [34]. In Africa, overall SARS-CoV-2 seroprevalence seemed to rise from 3% in April–June 2020 to 65% in

| Characteristic                                  | N   | Crude OR (95% CI) | p-value | Adjusted OR (95% CI) | p-value | Overall p-value |
|------------------------------------------------|-----|-------------------|---------|----------------------|---------|-----------------|
| Breadth of malaria antigen recognition          |     |                   |         |                      |         | 0.001           |
| Antigen recognition                             | 501 | 1.17 (1.01–1.36)  | 0.04    | 0.99 (0.83–1.18)     | 0.91    |                 |
| Malaria prevalence by mRDT                      |     |                   |         |                      |         |                 |
| Neg                                             | 445 | Ref               | Ref     | Ref                  | Ref     |                 |
| Pos                                             | 56  | 1.48 (0.84–2.59)  | 0.17    | 1.21 (0.64–2.28)     | 0.56    |                 |
| Age of participants                             |     |                   |         |                      |         |                 |
| Age in years                                    | 501 | 1.12 (1.08–1.17)  | 0.001   | 1.12 (1.07–1.17)     | 0.001   |                 |

Bold indicates \( p \)-values < 0.05

**Table 4** The association of SARS-CoV-2 seroprevalence and demographic and clinical data

| Characteristic       | N   | Crude OR (95% CI) | p-value | Overall p-value | Adjusted OR (95% CI) | p-value | Overall p-value |
|----------------------|-----|-------------------|---------|-----------------|----------------------|---------|-----------------|
| Age of participants  |     |                   |         | 0.001           |                      |         |                 |
| Age in years         | 501 | 1.12 (1.08–1.17)  | 0.001   | 1.13 (1.08–1.19) | 0.001               |         |                 |
| Village of residence |     |                   |         |                 |                      |         |                 |
| Mkokola              | 234 | Ref               | Ref     | Ref             | Ref                  |         |                 |
| Kwamasimba           | 267 | 1.37 (0.95–1.98)  | 0.09    | 1.24 (0.83–1.86) | 0.28                |         |                 |
| Haemoglobin levels   |     |                   |         |                 |                      |         |                 |
| Hb                   | 501 | 1.13 (1.00–1.27)  | 0.05    | 0.99 (0.86–1.13) | 0.86                |         |                 |
| Cough                |     |                   |         |                 |                      |         |                 |
| Yes                  | 170 | Ref               | Ref     | Ref             | Ref                  |         |                 |
| No                   | 330 | 1.36 (0.92–2.01)  | 0.12    | 1.19 (0.78–1.82) | 0.41                |         |                 |
| Body pain            |     |                   |         |                 |                      |         |                 |
| Yes                  | 20  | Ref               | Ref     | Ref             | Ref                  |         |                 |
| No                   | 444 | 0.46 (0.19–1.14)  | 0.09    | 0.73 (0.28–1.86) | 0.51                |         |                 |
| NA                   | 34  | 0.34 (0.10–1.08)  | 0.07    | 1.69 (0.46–6.15) | 0.43                |         |                 |

Bold indicates \( p \)-values < 0.05
July–September 2021 [17], up to ~87% by December 2021, mainly due to infection [34], whereas in high-income countries in Europe seroprevalence rose to ~96% due to infection and vaccination [34]. The antibody titers were at similar levels as the tested convalescent samples used. COVID-19 in children and adolescents is associated with asymptomatic or mild illness and much lower mortality than in adults [35]. Whether or not the seropositive participants had symptoms at the time of infection, diagnosis was not available to establish actual infection of SARS-CoV-2 and the different levels of antibody titer may represent different time from infection to antibody measurement. Furthermore, we did not test the neutralizing potential of the detected antibodies.

In countries in North America and Europe public health measures, such as school closures, have minimized children’s exposure to SARS-CoV-2 but seroprevalence of SARS-CoV-2 antibodies seem similar irrespective of age [36, 37]. Interestingly, in our study, the adolescents showed markedly higher seroprevalence than the children, which could be due to a more social and risk-taking behaviour of adolescents [38]. It is well known that maternal IgG can be obtained by the fetus

| Characteristic          | N     | Crude OR (95% CI) | p-value | Overall p-value | Adjusted OR (95% CI) | p-value | Overall p-value |
|-------------------------|-------|-------------------|---------|----------------|----------------------|---------|----------------|
| Age of participants     |       |                   |         |                |                      |         |                |
| Age in years            | 501   | 1.16 (1.12–1.20)  | 0.001   | 1.12 (1.08–1.16)| 0.001                |         |                |
| Village of residence    |       |                   |         |                |                      |         |                |
| Mkokola                 | 234   | Ref               | Ref     | Ref            |                      |         |                |
| Kwamasimba              | 267   | 1.88 (1.35–2.60)  | 0.001   | 1.91 (1.34–2.71)| 0.001                |         |                |
| Bed net use             |       |                   |         |                |                      |         |                |
| Yes                     | 480   | Ref               | Ref     | Ref            |                      |         |                |
| No                      | 19    | 3.95 (1.64–9.51)  | 0.002   | 2.27 (0.87–5.88)| 0.09                 |         |                |
| Fever                   |       |                   |         |                |                      |         |                |
| Yes                     | 111   | Ref               | Ref     | Ref            |                      |         |                |
| No                      | 389   | 0.45 (0.31–0.68)  | 0.001   | 0.41 (0.25–0.67)| 0.001                |         |                |
| Cough                   |       |                   |         |                |                      |         |                |
| Yes                     | 170   | Ref               | Ref     | Ref            |                      |         |                |
| No                      | 330   | 1.26 (0.90)       | 0.18    | 1.20 (0.83–1.74)| 0.32                 |         |                |
| Body weakness           |       |                   |         |                |                      |         |                |
| Yes                     | 19    | Ref               | Ref     | Ref            | Ref                  |         |                |
| No                      | 452   | 0.39 (0.17–0.89)  | 0.03    | 1.00 (0.36–2.80)| 1.00                 |         |                |
| NA                      | 29    | 0.06 (0.02–0.17)  | 0.001   | 1.27 (0.0–18.54)| 0.86                 |         |                |
| Headache                |       |                   |         |                |                      |         |                |
| Yes                     | 110   | Ref               | Ref     | Ref            | Ref                  |         |                |
| No                      | 360   | 0.40 (0.27–0.59)  | 0.001   | 0.65 (0.40–1.07)| 0.09                 |         |                |
| NA                      | 30    | 0.05 (0.02–0.12)  | 0.001   | 0.06 (0.01–0.46)| 0.01                 |         |                |
| Body pain               |       |                   |         |                |                      |         |                |
| Yes                     | 20    | Ref               | Ref     | Ref            | Ref                  |         |                |
| No                      | 444   | 0.60 (0.60–0.26)  | 0.21    | 2.83 (1.03–7.75)| 0.04                 |         |                |
| NA                      | 34    | 0.10 (0.03–0.27)  | 0.001   | 4.35 (0.50–37.61)| 0.18                 |         |                |
| Abdominal pain          |       |                   |         |                |                      |         |                |
| Yes                     | 99    | Ref               | Ref     | Ref            | Ref                  |         |                |
| No                      | 368   | 0.69 (0.46–1.04)  | 0.08    | 0.85 (0.55–1.33)| 0.48                 |         |                |
| NA                      | 32    | 0.10 (0.05–0.23)  | 0.001   | 1.63 (0.25–10.78)| 0.61                 |         |                |
| Loss of appetite        |       |                   |         |                |                      |         |                |
| Yes                     | 23    | Ref               | Ref     | Ref            | Ref                  |         |                |
| No                      | 452   | 0.37 (0.17–0.80)  | 0.01    | 0.67 (0.28–1.56)| 0.35                 |         |                |
| NA                      | 25    | 0.05 (0.02–0.16)  | 0.001   | 0.53 (0.06–4.93)| 0.58                 |         |                |

Bold indicates p-values < 0.05
protecting the baby after birth [39]. The titre of SARS-CoV-2 IgG in infants has been shown to correlate to that of their mothers [40]. This may explain why infants in our study showed higher recognition of SARS-CoV-2 than the children 1–4 and 5–9-year-old age groups, in particular among the infants under 6 months of age.

The seroprevalence of SARS-CoV-2 varied markedly among geographic regions early in the pandemic and was higher in high-income countries with very high human development index levels [36], however, uneven access to health care and diagnostics, and self-medicating practices outside the health system may also be reasons for the geographic variation [16, 34, 41]. Recently, the exposure to SARS-CoV-2 has also been associated with disadvantageous living conditions and overcrowded households [42]. In a (preprint) meta-analysis of the seroprevalence in Africa, the highest seroprevalences were found in adults (vs. children) and in urban areas (vs. rural) [17] with Africa being the world’s second-most populous continents, but also one of the least urbanized [43]. The observed seroprevalences in our study are below of what has been reported in other studies on the African continent at that time [17], however, we investigated only children and adolescents in rural areas. In Tanzania, the government did not implement a lockdown and with the limited testing facility available little is known about the overall exposure of SARS-CoV-2 and one can only guess at what the exposure has been in in densely populated cities, such as Dar es Salaam. Archived blood samples, if available, may shed light on the epidemiology of SARS-CoV-2 during the pandemic in Tanzania.

Previous exposure to SARS-CoV-2-like virus inducing cross-reactive antibodies have been shown using ELISA in both Sierra Leone (52% cross-reactivity) and the Democratic Republic of Congo (19.2% cross-reactivity) [12, 13], respectively. In our study, IgG from archived plasma samples collected in the same two villages of our study, before the pandemic, only two out of 100 individuals reacted with the SARS-CoV-2 spike protein used here (wild-type sequence [28]; Express2ion Biotechnologies), encompassing both the S1 and S2 subunits [44] with the used cut-off. This lack of reactivity indicates that cross-reactivity in our setting may be due to our plasma samples being taken from children and adolescents or because different recombinant proteins were used. The study in Sierra Leone used a recombinant N-protein [12], whereas in Congo [13] an N-protein, S1 protein, the receptor binding domain (RBD) of the S1 protein, the N-terminal domain of the S1 protein, and the S2 protein was used, only showing no cross-reactivity to the RBD. However, as the individuals, defined as being either SARS-CoV-2 seropositive or negative in our study, actual COVID-19 infections were not confirmed by PCR; hence we may risk mislabelling certain individuals with the used cut-off, potentially underestimating the cross-reactivity.

Medical conditions such as cancer, chronic lung diseases, heart conditions, diabetes, but as well as infectious diseases such as tuberculosis [45] and HIV [46] have been associated with higher risk of severe illness from COVID-19. In our study, we had the opportunity to investigate the individual seroprevalence with that of a coinciding malaria infection and previous exposure to P. falciparum. It has been hypothesized that co-infections or a recent history of malaria infection could be protective of COVID-19 severity and mortality [14, 15]. However, we did not find any association, negative or positive, when adjusting for the age-related increased exposure to both pathogens.

This current study was limited by an overall malaria prevalence of only 5.2% by blood smear microscopy (11.2% by mRDT) and by not investigating coinciding SARS-CoV-2 infections using PCR or IgM, or severe illness from COVID-19 infection. Furthermore, the used questionnaire was not designed to capture clinical information linked to a potential SARS-CoV-2 infection since this study was done on already collected samples from a malarometric cross-sectional survey. A longitudinal cohort study would have been more appropriate to investigate an association of the history of malaria exposure and the incidence of COVID-19 infections.

We did, however, find a higher serorecognition of malaria antigens in Kwamasimba, in particular among the 1–4-year-olds, which indicates a higher prior exposure to malaria parasites [31] as reflected in the prevalence and parasitaemia, both being more than twice as high in Kwamasimba than in Mkokola. A broader recognition of antigens associated with fewer cases of fever, but also with lower levels of haemoglobin which could indicate higher protection from apparent symptoms but not from increased risk of anaemia [27].

**Conclusion**

We found that more than a third of children and adolescents in rural Tanzania were having antibodies to SARS-CoV-2. This was almost one and a half year into the pandemic, few days prior to the highest number of recorded cases in the country, prior COVID-19 vaccination, and prior to the rapid spreading of the omicron variant (B.1.1.529) [47]. In a country that did not implement lockdown, natural immunity may have developed fast, potentially protecting a substantial part of the population from later variants such as the omicron [48].
**Supplementary Information**

The online version contains supplementary material available at https://doi.org/10.1186/s12879-022-07820-6.

**Additional file 1.** Baseline characteristics of the study populations from before the COVID-19 pandemic.

**Additional file 2** The number of SARS-CoV-2 seropositive and negative infants in Kwamasimba and Mkolkola villages based on age in months.

**Acknowledgements**

We thank the Tanzanian volunteers for participating in the study. We also thank Expression Biotechnologies for supplying the SARS-CoV-2 spike protein and Prof. Michael Theisen (University of Copenhagen), for supplying the MSP3 and GLURP R2 domains. We also thank all staff at NIRMR Korogwe Research Laboratory for assisting in data collection, laboratory analyses and data management.

**Author contributions**

EL conceptualised the study, conducted the study, wrote the first draft, edited the manuscript, led the laboratory analyses, performed the laboratory analysis, and conducted data analysis. AM, JM, PMH, EL, SG and LT conducted the study. JPAL, DTRM conceptualised the study, conducted the study, and edited the manuscript. TL conceptualised the study, conducted the study, edited the manuscript, and led the laboratory analysis. CF edited the manuscript and led laboratory analysis. CWW conceptualised the study, conducted the study, wrote the first draft, edited the manuscript, and led the laboratory analysis. All authors reviewed the manuscript. All authors read and approved the final manuscript.

**Funding**

The study was funded by the Malaria Research and Capacity building for field trials in Tanzania (MaReCa) project as part of the EDCTP2 programme supported by the European Union (Grant number THA2105SSF-998-MaReCa awarded to JPAL), and the Lundbeck Foundation (R344-2020-934 awarded to TL).

**Availability of data and materials**

The datasets used and analysed in this study are available from the grant holder (JPAL) through the corresponding author (EL) on reasonable request.

**Declarations**

**Ethics approval and consent to participate**

This study received ethical approval from Tanzania’s Medical Research Coordinating Committee (MRCC). Informed consent and/or assent was obtained from all subjects and/or their legal guardian(s). During the survey the Swahili language was used to convey oral and written information about the study objectives, procedures, confidentiality, and voluntary participation. Prior to the signing of the informed consent or assent forms, participants were given an opportunity to query any of the study’s objectives or procedures. Witnesses assisted with the informed consent or assent for study participants who were unable to read or write. All methods were carried out in accordance with relevant guidelines and regulations.

**Consent for publication**

Not applicable.

**Competing interests**

The authors declare that they have no competing interests.

**Author details**

1National Institute for Medical Research, Tanga Research Centre, P.O. Box 5004, Tanga, Tanzania. 2Department of Immunology and Microbiology, Centre for Medical Parasitology, University of Copenhagen, Copenhagen, Denmark. 3AdaptViac Aps, Ole Maalees Vej 5, 2200 Copenhagen N, Denmark. 4Department of Infectious Diseases, Copenhagen University Hospital, Copenhagen, Denmark.

**Received: 2 June 2022   Accepted: 29 October 2022**

Published online: 12 November 2022

**References**

1. Li Q, Guan X, Wu P, et al. Early transmission dynamics in Wuhan, China, of novel coronavirus-infected pneumonia. N Engl J Med. 2020;382(13):1199–207.
2. Wang D, Hu B, Hu C, et al. Clinical characteristics of 138 hospitalized patients with 2019 novel coronavirus–infected pneumonia in Wuhan, China. JAMA. 2020;323(11):1061–9.
3. Wang MY, Zhao R, Gao LJ, et al. SARS-CoV-2: structure, biology, and structure-based therapeutics development. Front Cell Infect Microbiol. 2020;10:587269.
4. Chan JF, Yuan S, Kok KH, et al. A familial cluster of pneumonia associated with the 2019 novel coronavirus indicating person-to-person transmission: a study of a family cluster. Lancet. 2020;395(10223):1119–27.
5. Coronavirus disease (COVID-19). https://www.who.int/health-topics/coronavirus#tab=table_3. Accessed 20 Apr 2022.
6. Johansson MA, Quandelacy TM, Kada S, et al. SARS-CoV-2 transmission from people without COVID-19 symptoms. JAMA Netw Open. 2021;4(1):e2035057.
7. Weiss DJ, Bertozzi-Villa A, Rumisha SF, et al. Indirect effects of the COVID-19 pandemic on malaria intervention coverage, morbidity, and mortality in Africa: a geospatial modelling analysis. Lancet Infect Dis. 2021;21(1):59–69.
8. World Health Organization. World malaria report 2021. Geneva: World Health Organization, 2021.
9. World Health Organization. World malaria report 2020. 20 years of global progress and challenges. Geneva: World Health Organization, 2020.
10. Cash R, Patel V. Has COVID-19 subverted global health? Lancet. 2020;395(10238):1687–8.
11. Mfinanga SG, Mnyambia NP, Minja DT, et al. Tanzania’s position on the COVID-19 pandemic. Lancet. 2021;397(10284):1542–3.
12. Borrega R, Nelson DK, Koval AP, et al. Cross-reactive antibodies to SARS-CoV-2 and MERS-CoV in pre-COVID-19 blood samples from Sierra Leoneans. Viruses. 2021;13(11):2325.
13. Souris M, Tshilolo L, Parzy D, et al. Pre-pandemic SARS-CoV-2 potential natural immunity among population of the Democratic Republic of Congo. medRxiv 2021:2021.2004.2028.21256243.
14. Kalungi A, Kinyanda E, Akena DH, et al. Less severe cases of COVID-19 in Sub-Saharan Africa: could co-infection or a recent history of Plasmodium falciparum infection be protective? Front Immunol. 2021;12:556625.
15. Osei SA, Biney RP, Anning AS, et al. Low incidence of COVID-19 case severity and mortality in Africa; Could malaria co-infection provide the missing link? BMC Infect Dis. 2022;22(1):78.
16. Six in seven COVID-19 infections go undetected in Africa. https://www.afro.who.int/news/six-seven-covid-19-infections-go-undetected-africa. Accessed 20 Apr.
17. Lewis HC, Ware H, Whelan MG, et al. SARS-CoV-2 infection in Africa: a systematic review and meta-analysis of standardised seroprevalence studies, from January 2020 to December 2021. BMJ Glob Health. 2022;7:e008793.
18. Coronavirus (COVID-19) Dashboard. https://covid19.who.int/region/africa/country/tz. Accessed 06th May 2022.
19. Yan R, Zhang Y, Li Y, et al. Structural basis for the recognition of SARS-CoV-2 by full-length human ACE2. Science. 2020;367(6485):1444–8.
20. Lan J, Ge J, Yu J, et al. Structure of the SARS-CoV-2 spike receptor-binding domain bound to the ACE2 receptor. Nature. 2020;581(7807):215–20.

21. Pinto D, Park YJ, Beltramello M, et al. Cross-neutralization of SARS-CoV-2 by a human monoclonal SARS-CoV antibody. Nature. 2020;583(7803):290–5.

22. Seydoux E, Homad LJ, MacCamy AJ, et al. Characterization of neutralizing antibodies from a SARS-CoV-2 infected individual. bioRxiv 2020.

23. Mkumbaye SI, Wang CW, Lymio E, et al. The severity of Plasmodium falciparum infection is associated with transcript levels of var genes encoding endothelial protein C receptor-binding Pf: falciparum erythrocyte membrane protein 1. Infect Immun. 2017;85(4):e00841-16.

24. Turner L, Lavstsen T, Berger SS, et al. Severe malaria is associated with parasite binding to endothelial protein C receptor. Nature. 2013;498(7455):502–5.

25. Adamou R, Dechavanne C, Sadissou I, et al. Plasmodium falciparum merozoite surface antigen-specific cytolytic IgG and control of malaria infection in a Beninese birth cohort. Malar J. 2019;18(1):194.

26. Mmbando BP, Vestergaard LS, Kitua AY, et al. A progressive declining in the burden of malaria in north-eastern Tanzania. Malar J. 2020;9:216.

27. Hayuma PM, Wang CW, Lihelu E, et al. Prevalence of asymptomatic malaria, submicroscopic parasitaemia and anaemia in Korogwe District, north-eastern Tanzania. Malar J. 2021;20(1):424.

28. Fougereoux C, Goksoyr L, Idorn M, et al. Capsid-like particles decorated with the SARS-CoV-2 receptor-binding domain elicit strong virus neutralization activity. Nat Commun. 2021;12(1):324.

29. Lardeux F, Torrico G, Aliaga C. Calculation of the ELISA’s cut-off based on the change-point analysis method for detection of Trypanosoma cruzi infection in Bolivian dogs in the absence of controls. Mem Inst Oswaldo Cruz. 2016;111(8):501–4.

30. First WHO International Standard Anti-SARS-CoV-2 Immunoglobulin (Human) NIBSC code: 20136. National Institute for Biological Standards and Control, Potters Bar, Herfordshire, EN6 3QG. WHO International Laboratory for Biological Standards, UK Official Medicines Control Laboratory. https://www.nibsc.org/products.aspx. Accessed 05 May 2022.

31. Turner L, Lavstsen T, Mmbando BP, et al. IgG antibodies to endothelial protein C receptor-binding cysteine-rich interdomain region domains of Plasmodium falciparum erythrocyte membrane protein 1 are acquired early in life in individuals exposed to malaria. Infect Immun. 2015;83(8):10906–103.

32. Turner L, Wang CW, Lavstsen T, et al. Antibodies against PFEMP1, RIFIN, MSP3 and GLURP are acquired during controlled Plasmodium falciparum malaria infections in naive volunteers. PLoS ONE. 2015;6(12):e29025.

33. Cham OK, Kurjis J, Lusingu J, et al. A semi-automated multiplex high-throughput assay for measuring IgG antibodies against Plasmodium falciparum erythrocyte membrane protein 1 (PFEMP1) domains in small volumes of plasma. Malar J. 2008;7:108.

34. Berger I, Whelan M, Ware H, et al. Global SARS-CoV-2 seroprevalence: a systematic review and meta-analysis of standardized population-based studies from Jan 2020–May 2022. 2022:2021.2012.2014.21267791.

35. O’Driscoll M, Ribeiro Dos Santos G, Wang L, et al. Age-specific mortality and immunity patterns of SARS-CoV-2. Nature. 2021;590(7844):140–5.

36. Rostami A, Sepidarkish M, Leeflang MMG, et al. SARS-CoV-2 seroprevalence and immunity in different age groups: a systematic review and meta-analysis. PLoS ONE. 2021;16(1):e0242886.

37. Song WM, Zhao JY, Zhang QY, et al. COVID-19 and tuberculosis coinfection: an overview of case reports/case series and meta-analysis. Front Med (Lausanne). 2021;8:65706.

38. Petersen E, Ntoumi F, Hui DS, et al. Emergence of new SARS-CoV-2 Variant of Concern Omicron (B.1.1.529)—highlights Africa’s research capabilities, but exposes major knowledge gaps, inequities of vaccine distribution, inadequacies in global COVID-19 response and control efforts. Int J Infect Dis. 2022;114:268–72.

39. Kim D, Ali ST, Kim S, et al. Estimation of serial interval and reproduction number to quantify the transmissibility of SARS-CoV-2 omicron variant in South Korea. Viruses. 2022;14(3):533.

Publisher’s Note
Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.